Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Background: Gut microbiota modulation using antibiotics can prevent progression of high sucrose diet (HSD) mediated
obesity and diabetes, through microbial metabolites, short chain fatty acids (SCFAs) and inflammatory mediators.
Aim: Present investigation was aimed to study the effect of altering the microflora of small intestine and colon in HSD rats by
oral administration of antibiotics in context with obesity and insulin sensitivity.
Methods: Rats were fed HSD with or without antibiotics administration for 60 days. The fecal microbiota communities,
metabolites, glucose tolerance, plasma and hepatic lipids profile, histological evaluation and gene expression were investigated.
Results: Simultaneous administration of HSD and antibiotics has shown significant improvements in glucose tolerance and
obesity associated parameters like hypercholesterolemia and hypertryglyceremia as compared to HSD. The qPCR study
of fecal samples showed marked increase in Lactobacillus and decrease in Enterobacteriaceae and E. coli in treated group,
which indicated the restoration of commensal microflora in direction to improvement in obesity and insulin sensitivity. Gas
chromatographic study indicated altered levels of the SCFAs such as butyrate and acetate (major source of the energy for gut
epithelial) in treated group as compared with HSD. Antibiotics co-administered group showed relatively less histopathological
symptoms, compared to HSD group. Treatment had decreased the gut derived Lipopolysaccharide, which further reduced
Immune Receptors expression along with reduced NF-kB activity to downregulate the expression of proinflammatory cytokines.
Future Prospects: Gut microbiota manipulation towards decreased inflammation and insulin resistance needs to be further
explored for its therapeutic applications in order to treat the metabolic complications.
Biography
Bhumika Prajapati has completed her MS Pharma in Biotechnology from National Institute of Pharmaceutical Education and Research (NIPER). She is currently perusing her PhD from Institute of Science, Nirma University. She has been awarded with Jawaharlal Nehru Scholarship for Doctoral Studies sponsored by Department of Science and Technology, India. Her work is mainly focused on the Gut microflora alteration in diet induced obesity and diabetes. She has published three papers in international journals